$MESO

Several biotech and pharma companies received regulatory approvals. MESO, LLY, ANIP, GRAL, AZN, TLSI, ABBV, RHHBY, MRK, AMRX, and ABEO gained approvals for various treatments. ABBV and RHHBY also announced strategic partnerships. LLY, GRAL, and ABBV saw notable stock price changes.

Mesoblast (NASDAQ: MESO, ASX: MSB) completed patient treatment in its Phase 3 trial for rexlemestrocel-L, a therapy for chronic low back pain, with 350 patients enrolled. The company reported US$36M in Q4 revenue for Ryoncil, totaling US$115M for the year. Mesoblast also secured US$103M in cash after extinguishing debt. The company is pursuing FDA approvals for expanded uses of Ryoncil and rexlemestrocel-L.

In 2024-2026, longevity advancements include FDA-approved MSC products, accelerated peptide approvals, and AI-designed drugs. GLP-1 medicines show cardiometabolic benefits. A gray market of wellness peptides exists, with FDA advisory votes on compounding. Mesoblast's Ryoncil gained FDA approval, and Longeveron's Laromestrocel targets aging-related conditions. Life Biosciences initiated a partial cellular reprogramming trial. Key players include Altos Labs, NewLimit, and Life Biosciences, with va

Mesoblast is conducting trials for RYONCIL in acute GVHD and Duchenne muscular dystrophy, with results expected in 2027. The company anticipates double-digit revenue growth and is pursuing approvals for rexlemestrocel-L in chronic low back pain and REVASCOR in heart failure. Mesoblast expects lower cash burn in fiscal 2027 and has a $125M credit facility.

MESOBLAST LTD (MESO) furnished an SEC Form 6-K — earnings release. MESOBLAST REPORTS SUBSTANTIAL REVENUE GROWTH TO US$120M RYONCIL Market Share Expands; Phase 3 Back Pain Trial Completes Treatment Financial Results and Operational Update for Full Year Ended June 30, 2026 New York, USA: August 26 and Melbourne, Australia: August 27, 2026: Mesobla

Mesoblast (MESO) shares rose about 9.5% after the company said it completed patient treatment in the MSB-DR004 pivotal Phase 3 trial of rexlemestrocel-L for chronic low back pain from degenerative disc disease. The trial enrolled 350 patients versus 300 planned. The primary endpoint targets durable pain reduction at 12 months, with FDA RMAT designation and a BLA submission targeted for Q3 2027.

Mesoblast Limited (Nasdaq:MESO) said it reached its target of at least 300 treated patients in the MSB-DR004 pivotal Phase 3 trial of rexlemestrocel-L for chronic low back pain due to degenerative disc disease. The primary endpoint compares pain reduction at 12 months vs sham. Top-line results are expected mid-2027.

Australia’s S&P/ASX 200 fell 0.41% to 8,770.2 by midday Monday as Middle East tensions and IMF warnings weighed on sentiment. The IMF cut Australia’s 2026 growth forecast to 1.9% and flagged inflation near 4%. Coles slid on a reported Greencross deal; Santos and Woodside were softer; Mesoblast was upgraded to buy with a $4.45 target.

ASX futures pointed to a 0.49% rise at the open after Wall Street ended higher, supported by AI and chip stocks. The ASX 200 rose 0.5% on Friday to 8,806, led by mining and financials. Telstra fell 1.6%, WiseTech 1.8%, while Mesoblast rose 6% on US$115m FY2026 revenue. Geopolitical Iran tensions and oil moves weighed on sentiment.

Mesoblast Limited (Nasdaq:MESO) reported Ryoncil net revenue of $36 million for the quarter ended June 30, 2026, and $115 million for the full fiscal year. The company said revenues exceeded initial projections and expects continued growth, citing uptake in major U.S. pediatric centers. Results are preliminary pending audit.